Astrazeneca Plc (LON:AZN) has announced that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC successfully priced four tranches of Eurobonds totalling €2.55 billion. The offering is expected to close on 1 September 2026, subject to customary closing conditions. This issuance is aligned with the company’s long term funding strategy.
The Offering consisted of the following notes, issued by AstraZeneca Finance LLC and fully and unconditionally guaranteed by the Company:
· €700 million of fixed rate notes with a coupon of 3.402% maturing on 1 March 2030;
· €600 million of fixed rate notes with a coupon of 3.652% maturing on 1 September 2032;
· €500 million of fixed rate notes with a coupon of 3.923% maturing on 1 September 2035; and
· €750 million of fixed rate notes with a coupon of 4.169% maturing on 1 September 2038 (together, the Notes).
The company expects to use the net proceeds of the offering for general corporate purposes.
Barclays Bank PLC, Goldman Sachs International and Morgan Stanley acted as joint book-running managers on the transaction.
The Notes will be issued under the Euro Medium Term Note (EMTN) programme of the Company and AstraZeneca Finance LLC and admitted to listing on the UK Financial Conduct Authority’s Official List and to trading on the London Stock Exchange’s Main Market.
The Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the Notes described herein, nor shall there be any sale of these Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
